An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas

References

• Sehn LH, Salles G, Longo DL. Diffuse large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842–858. doi: 10.1056/NEJMra2027612
   PubMed Web of Science ®Google Scholar
• Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma in transplant-ineligible patients: primary analysis of alycante, a phase 2 Lysa Study. Blood. 2022;140:410–411. doi: 10.1182/blood-2022-156626
   Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Messori A, Rivano M, Mengato D, et al. Treatments for relapsed-refractory diffuse large B-cell lymphoma: a preliminary evaluation of the place in therapy of Glofitamab, a bispecific monoclonal antibody. Cureus. 2022;14:e33169. doi: 10.7759/cureus.33169
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Hunter B, Armand P, et al. Axicabtagene Ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132(Supplement 1):92–92. doi: 10.1200/JCO.19.02103
   Google Scholar
• Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790–800. doi: 10.1016/S1470-2045(21)00139-X
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. Blood. 2018;132(Supplement 1):1683–1683. doi: 10.1182/bloodadvances.2021005794
   Google Scholar
• Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307–2315. doi: 10.1182/blood.2022018893
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi: 10.1016/S1470-2045(20)30225-4
   PubMed Web of Science ®Google Scholar
• Qualls DA, Lambert N, Caimi PF, et al. Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023;142(26):2327–2331. doi: 10.1182/blood.2023021274
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell–engaging antibody, in relapsed or refractory large B-Cell Lymphoma: dose expansion in a phase I/II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(12):2238–2247. doi: 10.1200/JCO.22.01725
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. 2022;387:2220–2231. doi: 10.1056/NEJMoa2206913
   PubMed Web of Science ®Google Scholar
• Sun Y, Yu X, Wang X, et al. Bispecific antibodies in cancer therapy: target selection and regulatory requirements. Acta Pharm Sin B. 2023;13(9):3583–3597. doi: 10.1016/j.apsb.2023.05.023
   PubMed Web of Science ®Google Scholar
• Bröske A-M, Korfi K, Belousov A, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-hodgkin lymphoma. Blood Adv. 2022;6(3):1025–1037. doi: 10.1182/bloodadvances.2021005954
   PubMed Web of Science ®Google Scholar
• Shirley M. Glofitamab: First Approval. Drugs. 2023;83:935–941. doi: 10.1007/s40265-023-01894-5
   PubMedGoogle Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-Cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell Lymphoma: a phase I trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(18):1959–1970. doi: 10.1200/JCO.20.03175
   PubMed Web of Science ®Google Scholar
• Hutchings M, Carlo-Stella C, Morschhauser F, et al. Relapse is uncommon in patients with large B-Cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment. Blood. 2022;140(Supplement 1):1062–1064. doi: 10.1182/blood-2022-157554
   Google Scholar
• Carlo-Stella C, Hutchings M, Offner F, et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with richter’s transformation. Hematol Oncol. 2023;41(S2):63–65. doi: 10.1002/hon.3163_28
   Google Scholar
• Birtas Atesoglu E, Gulbas Z, Uzay A, et al. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: real-world data. Hematol Oncol. 2023;41(4):663–673. doi: 10.1002/hon.3174
   PubMed Web of Science ®Google Scholar
• Dodero A, Bramanti S, Di Trani M, et al. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas. Br J Haematol. 2023;n/a(1):151–159. doi: 10.1111/bjh.19057
   Google Scholar
• Dickinson M, Carlo-Stella C, Morschhauser F, et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: pivotal phase II expansion results. J Clin Oncol. 2022;40:7500. doi: 10.1200/JCO.2022.40.16_suppl.7500
   Web of Science ®Google Scholar
• Hutchings M, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in relapsed or refractory large B-Cell Lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-Cell therapy and by baseline total metabolic tumor volume. Blood. 2023;142(Supplement 1):433. doi: 10.1182/blood-2023-173951
   Google Scholar
• Phillips TJ, Dickinson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Blood. 2022;140(Supplement 1):178–180. doi: 10.1182/blood-2022-157777
   Google Scholar
• Morschhauser F, Carlo-Stella C, Dickinson M, et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) Follicular Lymphoma (FL). Blood. 2021;138(Supplement 1):128. doi: 10.1182/blood-2021-148778
   Google Scholar
• Song Y-Q, Zhang H-L, Huang H-Q, et al. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2023. doi:10.3324/haematol.2023.283802
   Google Scholar
• Rentsch V, Seipel K, Banz Y, et al. Glofitamab treatment in relapsed or refractory DLBCL after CAR T-Cell therapy. Cancers (Basel). 2022;14(10):14. doi: 10.3390/cancers14102516
   Web of Science ®Google Scholar
• Hutchings M, Avigdor A, Sureda A, et al. Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed/refractory diffuse large B-Cell lymphoma. Hematol Oncol. 2023;41:138–140. doi: 10.1002/hon.3163_92
   Google Scholar
• Minson A, Verner E, Giri P, et al. Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients ≤65 years of age with high-risk DLBCL: interim analysis of coalition. Hematol Oncol. 2023;41:421–422. doi: 10.1002/hon.3164_309
   Google Scholar
• Topp MS, Tani M, Dickinson M, et al. Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with Previously untreated diffuse large B-Cell lymphoma (DLBCL): results from a phase ib study. Blood. 2022;140:1775–1777. doi: 10.1182/blood-2022-157732
   Web of Science ®Google Scholar
• Dickinson M, Viardot A, Marks R, et al. Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase ib study. J Clin Oncol. 2023;41:7549. doi: 10.1200/JCO.2023.41.16_suppl.7549
   Google Scholar
• Hutchings M, Dickinson M, Carlo-Stella C, et al. Combining CD19-4-1BBL (RO7227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory b-cell non-hodgkin lymphoma. Hematol Oncol. 2023;41:136–138. doi: 10.1002/hon.3163_91
   PubMedGoogle Scholar
• Hutchings M, Carlo-Stella C, Gritti G, et al. CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell-engaging bispecific antibody glofitamab in relapsed or refractory B-Cell Non-Hodgkin Lymphoma. Blood. 2022;140:9461–9463. doi: 10.1182/blood-2022-157011
   Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in Previously untreated diffuse large B-Cell Lymphoma. N Engl J Med. 2021;386(4):351–363. doi: 10.1056/NEJMoa2115304
   PubMed Web of Science ®Google Scholar
• Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327–e339. doi: 10.1016/S2352-3026(22)00072-2
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285–295. doi: 10.1016/j.ymthe.2016.10.020
   PubMed Web of Science ®Google Scholar
• Jaglowski S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell therapy for adults with diffuse large B-Cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry. Blood. 2019;134(Supplement_1):766. doi: 10.1182/blood-2019-130983
   Google Scholar
• Palomba ML, Garcia J, Wang L, et al. TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) healthcare resource utilization in patients with relapsed/refractory diffuse large B-Cell lymphoma (DLBCL). Blood. 2018;132(Supplement 1):3545–3545. doi: 10.1182/blood-2018-99-119387
   Google Scholar
• Crochet G, Audrey C, Bachy E, et al. CAR T-Cell therapy remain effective in patients with relapse/refractory b-cell non-hodgkin lymphoma after bispecific antibodies exposure: results of a lysa study based on the descar-t registry. Blood. 2022;140:4639–4641. doi: 10.1182/blood-2022-162594
   Google Scholar
• Hutchings M. The evolving therapy of DLBCL: bispecific antibodies. Hematol Oncol. 2023;41(S1):107–111. doi: 10.1002/hon.3154
   PubMedGoogle Scholar